Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Total Current Liabilities of $12.1 million for Q1 2026, up 30.51% year-over-year from $9.3 million in Q1 2025, and up 29.1% quarter-over-quarter from $9.4 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 30.51% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $12.1 million (up 30.51% YoY), while the FY2025 annual figure was $9.4 million, down 73.5% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $12.1 million, up from $9.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $46.4 million in Q3 2024, with the low at $6.7 million in Q1 2024.
- The 5-year median for Total Current Liabilities is $9.3 million (2025), against an average of $13.2 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 535.79% in 2024, then sank 82.6% in 2025.
- Corvus Pharmaceuticals' Total Current Liabilities stood at $10.8 million in 2022, then slumped by 36.11% to $6.9 million in 2023, then surged by 415.39% to $35.4 million in 2024, then sank by 73.5% to $9.4 million in 2025, then advanced by 29.1% to $12.1 million in 2026.
- Business Quant data shows CRVS's Total Current Liabilities at $12.1 million in Q1 2026, $9.4 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 13.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.67 Mn |
| Mar 31, 2026 | 12.11 Mn |
| Dec 31, 2025 | 9.38 Mn |
| Sep 30, 2025 | 8.07 Mn |
| Jun 30, 2025 | 8.51 Mn |
| Mar 31, 2025 | 9.28 Mn |
| Dec 31, 2024 | 35.40 Mn |
| Sep 30, 2024 | 46.41 Mn |
| Jun 30, 2024 | 13.34 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Dec 31, 2023 | 6.87 Mn |
| Sep 30, 2023 | 7.30 Mn |
| Jun 30, 2023 | 7.86 Mn |
| Mar 31, 2023 | 8.29 Mn |
| Dec 31, 2022 | 10.75 Mn |
| Sep 30, 2022 | 13.98 Mn |
| Jun 30, 2022 | 10.16 Mn |
| Mar 31, 2022 | 9.27 Mn |
| Dec 31, 2021 | 9.69 Mn |
| Sep 30, 2021 | 11.31 Mn |